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The utility of plasma amyloid beta (Aβ) and tau levels for the clinical diagnosis of
Alzheimer’s disease (AD) dementia has been controversial. The main objective of
this study was to compare Aβ42 and tau levels measured by the ultra-sensitive
immunomagnetic reduction (IMR) assays in plasma samples collected at the Banner
Sun Health Institute (BSHRI) (United States) with those from the National Taiwan
University Hospital (NTUH) (Taiwan). Significant increase in tau levels were detected in
AD subjects from both cohorts, while Aβ42 levels were increased only in the NTUH
cohort. A regression model incorporating age showed that tau levels identified probable
ADs with 81 and 96% accuracy in the BSHRI and NTUH cohorts, respectively, while
computed products of Aβ42 and tau increased the accuracy to 84% in the BSHRI
cohorts. Using 382.68 (pg/ml)2 as the cut-off value, the product achieved 92% accuracy
in identifying AD in the combined cohorts. Overall findings support that plasma Aβ42 and
tau assayed by IMR technology can be used to assist in the clinical diagnosis of AD.
Keywords: plasma, amyloid β, tau, Alzheimer’s disease, immunomagnetic reduction assay
INTRODUCTION
Definitive diagnosis of Alzheimer’s disease (AD) is based on neuropathological criteria for the
density of amyloid and neuritic plaques, primarily composed of amyloid beta (Aβ) peptides,
and neurofibrillary tangles, primarily composed of aggregated and phosphorylated tau (ptau).
The constituents of these pathological hallmarks have been intensely investigated as diagnostic
biomarkers for early AD in living subjects. There has been increasing use of positron emission
tomography (PET) to detect fibrillar Aβ and tau pathologies in living subjects, along with
biochemical measurements of Aβ42, Aβ40, tau, and ptau in the cerebrospinal fluid (CSF), for
research and clinical studies of AD (Galasko et al., 1998; Shaw et al., 2009; Trojanowski et al., 2010;
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Molinuevo et al., 2014; Beckett et al., 2015; Kang et al., 2015;
Kleinschmidt et al., 2015; Weiner et al., 2015; Leuzy et al., 2016).
However, clinical imaging is limited by high cost, while lumbar
puncture for CSF collection is not a readily acceptable procedure
for many elderly patients (Lowery and Oliver, 2008; Amorim
et al., 2012; Zetterberg et al., 2013; Alcolea et al., 2014; Duits
et al., 2015). In addition, there is still lack of consensus as to how
CSF profiles of Aβ42, tau, and ptau should be used in clinical
settings for disease diagnosis (Dumurgier et al., 2013; Blennow
et al., 2015).
Blood is an inexpensive and convenient source for developing
disease biomarkers. Well-validated blood biomarker panels could
assist in diagnosis, patient screening for clinical trials, and follow-
up studies. To date, the levels of Aβ, tau, and ptau measured
in plasma or serum samples reported in the literature have
been inconsistent [reviewed in (Hampel et al., 2010; Toledo
et al., 2013)]. The concentrations of these markers in plasma
or serum are 10- to 100-fold lower than in CSF, which has
caused challenges for accurate and reliable measurement when
conventional enzyme-linked immunosorbent assays (ELISA)
have been used (Rissin et al., 2013; Blennow and Zetterberg,
2015b).
To meet the need of higher detection sensitivity, new
technologies have been developed (Hye et al., 2006; Yang et al.,
2011; Chang et al., 2012; Irwin et al., 2012; Mattsson et al.,
2013). Among these technologies, immunomagnetic reduction
(IMR) assays can sensitively quantify levels of Aβ and tau
in biofluids by detecting the reduction in magnetic signals
after binding of magnetic nanobead-conjugated antibody to the
target analytes using a high-sensitivity magneto-susceptometer,
a superconducting quantum interference device (SQUID) (Yang
et al., 2011).
Studies in Taiwanese cohorts using this technology showed
significant increases in Aβ42 and tau concentrations in plasma
samples of subjects with mild cognitive impairment (MCIs) due
to AD, and in early-stage AD (Chiu et al., 2012). A similar
study also showed that the computed products of Aβ42 and
tau increased the sensitivity for discriminating normal controls
(NCs) from early AD subjects (ADs), and MCIs from early ADs
(Chiu et al., 2013).
While previous IMR studies have provided promising
findings, the assays have not been independently confirmed
in other cohorts of different ethnicity. To achieve this, we
recruited a cohort of NC and AD subjects from the Banner
Sun Health Research Institute (BSHRI) (Sun City, AZ, United
States) to provide plasma samples for IMR assays. We compared
the plasma levels of Aβ42 and tau in the BSHRI cohort
with those of samples collected independently at the National
Taiwan University Hospital (NTUH). Using the same statistical
approach, we determined the ability of these measures to
distinguish ADs from NCs in both cohorts. To further explore
the utility of plasma Aβ, Aβ42, and tau levels for AD diagnosis
across age and population, we developed new statistical models
that incorporated age along with the levels of these biochemical
analytes to establish cut-off values for identifying AD in the
combined data from the BSHRI and NTUH cohorts. The findings
confirmed that plasma Aβ42 and tau levels detected by IMR
technology achieved exceptional accuracy of diagnosis and thus
have potential to be further developed as blood biomarkers for
assisting in the clinical diagnosis of AD.
MATERIALS AND METHODS
Participants
BSHRI Site (United States)
The participants consisted of 16 healthy non-demented control
subjects (NCs) who were also enrolled in the Arizona Study of
Aging and Neurodegenerative Disorders (ASAND), and 16 age-
matched subjects clinically diagnosed as probable Alzheimer’s
dementia (ADs) by a dementia neurologist. The recruitment
period was from January to July, 2014.
All participants were 65 years or older, from both genders,
and with a minimum secondary school education. Probable
AD dementia subjects received this diagnosis according to the
2011 NIA-AA diagnostic guidelines with Functional Assessment
Staging (FAST) scores of 4–6 and Mini Mental State Examination
(MMSE) scores of 10–20. The inclusion criteria of NCs were
subjects without depression syndrome, with FAST scores of 1–
2 and MMSE scores of 28–30. Although NCs had been assessed
with a battery of neuropsychological tests as a consequence
of participation in ASAND, we only included MMSE in
statistical analysis because neuropsychological assessments of
non-ASAND participants had been limited to this measure.
Subjects with medical history of major systemic diseases that
could affect cognitive functions, including cardiopulmonary
failure, hepatic or renal failure, diabetes, head injury, stroke or
other neurodegenerative disease, were excluded.
NTUH Site (Taiwan)
This study consisted of 63 NCs and 31 ADs. The recruitment
of the subjects was described previously (Chiu et al., 2012).
NCs received physical and neurological examinations and were
scored less than 9 on a short-form Geriatric Depression Scale
(GDS-S) and confirmed as cognitively normal with a battery
of neuropsychological tests. Subjects with AD were recruited
from the memory clinic at the NTUH and fulfilled the
NINCDS/ADRDA criteria for probable AD (McKhann et al.,
1984).
Approval of Human Subject Protocols
Both BSHRI and NTUH studies were conducted according to
human subject study protocols approved, respectively, by the
Institutional Review Boards of the two study sites (BSHRI:
Western Institutional Review Board, www.wirb.com; NTUH:
National Taiwan University Hospital Institutional Review Board).
Subject enrollment and consenting processes were conducted
by qualified personnel. Written informed consent was obtained
from each participant or a qualified representative (spouse or
family member).
Blood Sample Processing
The plasma samples were collected for this study employing
centrifugation speeds of 2,500 × g. This differed from the ADNI
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recommended protocol of 1,500 × g, but was used to ensure
consistency with previous studies using IMR-based assays (Chiu
et al., 2013). Approximately 16 ml of whole blood was collected
into EDTA-treated tubes. Samples were centrifuged at 2,500 × g
for 15 min at room temperature within 15 min of the blood draw.
Plasma was removed, aliquoted into various volumes, and stored
at −80◦C. White blood cell pellets were used for determination
of apolipoprotein E (ApoE) genotype from each case recruited at
BSHRI; the ApoE genotypes were not available from the subjects
recruited at NTUH site. Frozen plasma aliquots were shipped on
dry ice to MagQu Co. Ltd.1 (New Taipei City, Taiwan) for IMR
assays. Assays were carried out without knowledge of individual
identification or diagnosis.
IMR Assays
The technical details of the IMR assays have been described
previously (Yang et al., 2011; Chiu et al., 2013, 2014; Tzen et al.,
2014). The selection of the antibodies conjugated to the IMR
reagents (MagQu Co. Ltd.; Catalog Numbers: MF-AB2-0060
and MF-TAU-0060) were based on epitopes, affinity to antigens,
ability to be conjugated onto MagQu magnetic nanobeads, and
the ability to provide linearity of standard curves quantified by
magnetic signal reduction. The company tested these reagents
in human plasma samples spiked with the proteins used for
making standards for measurement accuracy. The amounts of
the proteins added were 95–1,038 pg/ml and 100–1,197 pg/ml
respectively for Aβ42, and tau. The recovery rates of these spiked
proteins, expressed in mean% (+standard error), were 98.98%
(+1.63) for Aβ42 and 96.75% (+2.26) for tau. To assay tau, 40 µl
of plasma sample was mixed with 80 µl IMR reagents at room
1www.magqu.com
temperature. To assay Aβ42, 60 µl of plasma sample was mixed
with 60 µl of IMR reagent.
The analyzer for IMR assays is a SQUID-based alternate
current (ac) magnetosusceptometer (model XacPro-S, MagQu
Co., New Taipei City, Taiwan). It detects magnetic signal
changes during the course of antigen and antibody interactions,
expressed as percentage reductions of immunomagnetic signals
(IMR%), which are then converted to sample concentrations
using values from the standard curves of the respective analytes.
The reduction of oscillation detected by SQUID corresponds to
the amounts of analytes bound to the antibodies.
Statistical Analysis
Basic hypothesis-testing analyses were performed using the
statistical package SPSS (version 22, IBM). All ROC analyses
and performance comparisons were completed using R2 (version
3.2.4). Two statistical objectives were set for both separate and
combined cohorts (Figure 1). First, we tested the hypothesis that
probable ADs are different from NCs in each of the analytes
(Aβ42 and tau) and in the ratios and products of Aβ42 and
tau. Age was included as a covariate in determinations of group
differences using analysis of covariance (ANCOVA).
Second, to examine the corresponding criteria of
distinguishing probable ADs from NCs to assist on clinical
diagnosis, we used receiver operational characteristics (ROC)
curve analysis. For adequate objective assessment, performance
metrics based on the area under the curve (AUC) of ROC
were compared using leave-one-out (LOO) cross-validation.
Sensitivity, specificity, overall accuracy, positive likelihood ratio,
negative likelihood ratio with their respective 95% confident
2http://www.R-project.org/
FIGURE 1 | Experimental design and statistical models.
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interval (CI) except AUC were computed based on the logistic
model. Age was included as an additional predictor together
with the concentrations of single Aβ42 or tau analytes, or their
combinations (ratios or products) in the logistic models.
RESULTS
Participant Features
The demographic features for the BSHRI, NTUH, and combined
cohorts are shown in Table 1 according to disease group. The
BSHRI participants were age- and gender-matched between
NCs and ADs. However, the ADs in the NTUH cohort were
significantly older than NCs (NCs: 64.4 + 1.1 years; ADs:
72.5 + 1.5 years, P = 0.003). Overall, the BSHRI cohort was
significantly older in both groups (NCs: 81.9 + 1.5 years;
ADs: 82.5 + 1.4 years). In the combined cohort, mean age
was 75.9 + 1.4 years in ADs and 64.1 + 1.3 years in NCs
(P = 0.0001). The MMSE scores of ADs compared to the
Taiwanese cohort (BSHRI: 16.13+ 0.97; NTUH: 22.7+ 3.2) were
significantly lower than those of NCs (BSHRI: 29.3+ 0.3; NTUH:
28.9 + 1.3; P < 0.001), indicating that ADs in BSHRI cohort
were cognitively more impaired than the ADs in NTUH cohort.
The MMSE scores of the combined cohort were 20.5 + 4.6 for
ADs and 28.7 + 1.3 for NCs (P < 0.0001). As we compared
the percentages of female subjects in each disease category, there
were no significant differences between diagnostic groups within
same cohort using Chi-squared analysis (NTUH: P = 0.1740;
BSHRI: P = 0.2658). The ApoE genotype information was only
available from the subjects recruited at the BSHRI site. Due
to small number of subjects in BSHRI, we only determine
the effect by the presence (carriers) or absence (non-carriers)
of ApoE ε4. The results of one-way ANOVA analysis showed
no statistical difference between non-carriers and carriers in
ApoE ε4 in the levels of Aβ42 (means + standard errors:
in NCs: non-carriers: 15.44 + 0.70 pg/ml, N = 10; carriers:
15.13 + 0.90 pg/ml, N = 6, P = 0.821; in ADs: non-carriers:
17.09 + 0.99 pg/ml, N = 5; carriers: 16.67 + 0.67 pg/ml, N = 11,
P= 0.622) or tau (means+ standard errors: in NCs: non-carriers:
19.22 + 3.61 pg/ml, N = 10; carriers: 22.59 + 4.66 pg/ml, N = 6,
P = 0.196; in ADs: non-carriers: 37.31 + 5.10 pg/ml, N = 5;
carriers: 33.25+ 3.44 pg/ml, N = 11, P = 0.633).
AD-Associated Variations in Plasma
Aβ42 and Tau Levels
We assessed if the levels of Aβ42 and tau in plasma showed
disease-associated differences in the individual cohorts, and when
the data were combined. Because of the presence of an age-effect,
ANOCOVA with age as a covariate was used when examining the
group analyte differences between ADs and NCs for the NTUH
and combined cohorts. The compiled data are shown in Table 2.
To illustrate the distribution patterns of the single analyte data,
scatter plots of Aβ42 and tau levels from individual cohorts are
shown in Figure 2.
In both cohorts, the levels of plasma tau were significantly
higher in ADs than in NCs (BSHRI: NCs: 20.48 + 1.24 pg/ml;
ADs: 34.52 + 3.75 pg/ml, P = 0.002; NTUH: NCs:
13.98+ 1.89 pg/ml; ADs: 52.47+ 2.72 pg/ml, P= 7.19× 10−17).
There was a small but significant increase in Abβ2 levels in the
AD group of the NTUH cohort (NCs: 15.81 + 0.14 pg/ml; ADs:
18.63 + 0.21 pg/ml, P = 3.63 × 10−16). This measure was not
significantly different in the BSHRI cohort (P = 0.063) as Aβ42
levels in the NC group had significant overlap with the values
from the AD group.
In the combined cohort, statistical significance for group
differences were detected in tau levels: ADs had significantly
higher tau levels (NCs: 14.89 + 0.81; ADs: 47.09 + 3.25,
P = 2.0 × 10−16) (Table 2). Although group differences
in Aβ42 levels were small (NCs: 15.72 + 0.16 pg/ml; ADs:
18.00 + 0.25 pg/ml, P = 3.6 × 10−16), they did reach the level
of significance. In addition to single analyte differences, ratio
(Aβ42/tau) and product (Aβ42 × tau) were also computed for
group comparison. All cohorts showed significant differences
between ADs and NCs (Table 2). The ratios of Aβ42 to tau were
lower in ADs, while the products of Aβ42 and tau were higher
in ADs (Table 2). The product of Aβ42 and tau was significantly
increased in ADs.
Receiver Operating Characteristic Curve
(ROC) Analysis
To further evaluate the utility of individual analytes, their ratios
or products in identifying probable AD, age was incorporated
into a model along with biochemical measures for ROC analysis
with LOO cross-validation. As shown in Table 3, single analytes
TABLE 1 | Age, gender, and MMSE scores in the studied cohorts.
Cohort BSHRI NTUH Combined
Group NC AD NC AD NC AD
Subject No. 16 16 61 31 77 47
Male:Female 4:12 7:9 24:37 17:14 28:49 24:23
Apo E4 carrier:Non-carrier 6:10 11:5 – – – –
Age, years 81.9 ± 1.5 82.5 ± 1.4 64.2 ± 1.1a 72.5 ± 1.8a 68.1 ± 1.3b 75.9 ± 1.4b
MMSE 29.3 ± 0.3c 16.1 ± 1.0c 28.9 ± 1.3d 22.7 ± 3.2d 28.7 ± 1.3e 20.5 ± 4.6e
Abbreviations: BSHRI, Banner Sun health Research Institute; NTUH, National Taiwan University Hospital; NC, normal controls; AD, Alzheimer’s disease; MMSE, Mini
Mental State Examination. Age and MMSE are shown in mean + standard errors. Lower case a to e: same letter denotes significant differences between the noted two
values based on two-sample independent t-test (P < 0.05). –: not calculated.
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TABLE 2 | Group differences in Aβ42 and tau and their computed ratios and products.
BSHRI NC# (N = 16) AD# (N = 16) Group differences (95% CI)& P-value+
Aβ42 15.33 ± 0.66 16.8 ± 0.37 1.48 (3.0,0.1) 0.063
Tau 20.48 ± 1.24 34.52 ± 3.75 14.0 (22.3,5.7) 0.002
Aβ42/tau 0.79 ± 0.07 0.55 ± 0.05 −0.24 (− 0.40,−0.07) 0.0061
Aβ42 × tau 316.43 ± 26.59 574.52 ± 57.80 258.1 (390.4,125.8) 0.0006
NTUH NC# (N = 61) AD# (N = 31) Group differences (95 % CI)& P-value±
Aβ42 15.81 ± 0.14 18.63 ± 0.21 2.82 (3.32,2.33) 3.63e-16
Tau 13.98 ± 1.89 52.47 ± 2.72 38.48 (44.98,31.99) 7.19e-17
Aβ42/Aβ 0.26 ± 0.012 0.52 ± 0.017 0.26 (0.30,0.21) 1.67e-17
Aβ42/tau 1.58 ± 0.11 0.43 ± 0.16 −1.14 (− 0.77,−1.52) 1.54e-07
Aβ42 × tau 222.28 ± 33.12 976.77 ± 47.77 754.49 (868.42,640.56) 6.18e-19
Combined NC# (N = 77) AD# (N = 47) Group differences (95 % CI)& P-value±
Aβ42 15.72 ± 0.16 18.00 ± 0.25 2.28 (1.68,2.87) 3.632e-13
Tau 14.89 ± 0.81 47.09 ± 3.25 32.20 (25.46,38.93) <2e-16
Aβ42/Aβ 0.27 ± 0.0048 0.46 ± 0.021 0.19 (0.15,0.24) <2e-16
Aβ42//tau 1.42 ± 0.11 0.46 ± 0.026 −0.97 (− 1.19,−0.74) 2.11e-10
Aβ42 × tau 235.50 ± 13.59 850.21 ± 59.04 614.71 (493.07,736.35) <2e-16
#Means and standard errors. &Group differences reflect the changes comparing to NC; when values in AD group are higher than NC group, the differences are negative;
the lower and upper limits at 95% confidence intervals (CI) are listed within parenthesis. +P-values from independent two-sample t-test. ±P-values from ANCOVA to
examine group differences with age as a covariate.
in the BSHRI group for tau achieved 81% accuracy in identifying
ADs in the BSHRI cohort, which was better than for single Aβ42
levels (69%). The accuracies for the ratio and product were 72 and
84%, respectively. With respect to the NTUH cohort, tau, Aβ42,
ratio, and product all had high accuracy of identifying probable
ADs.
To explore the feasibility of establishing general criteria for
identifying clinical AD across populations and age, we tested a
prediction model in the combined cohort, which had subjects
covering a broader age distribution and disease severity. Table 4
summarizes the results from the combined cohorts, including
sensitivity, specificity, and positive and negative likelihood ratios
(LR). The cut-off values were also included in the table. The only
measure that had an age-dependent cut-off value was Aβ42. Both
single analytes performed well in terms of sensitivity, specificity,
AUC, and accuracy. The model of Aβ42-to-tau ratio with age gave
83% sensitivity and 94% specificity. The product Aβ42× tau with
age had highest AUC (0.98, P = 2.55 × 10−19), along with 94%
sensitivity, 92% specificity, 92% accuracy,+LR value at 9.22, and
−LR value at 0.047.
DISCUSSION
In this study, we showed that IMR technology provided a high-
sensitivity assay platform for reliably measuring plasma Aβ42
and tau in blood allowing for discrimination between NCs
and clinically diagnosed ADs. This was demonstrated in two
independently recruited cohorts in this study. In both cohorts,
data confirmed that plasma tau levels from IMR assays had high
degrees of sensitivity and specificity, which was enhanced by
including computed ratios and products, Aβ42, along with age to
distinguish ADs from NCs. With high-sensitivity and specificity
not previously seen by other assay platforms, we developed
regression models that showed the power of discrimination these
measures provide. In separate cohorts, the regression model
incorporating age and tau level had 81 and 96% accuracy in
identifying probable AD in the BSHRI and NTUH, respectively;
incorporating age with the products of Aβ42 and tau had 84%
accuracy in the BSHRI cohort and 95% accuracy in the NTUH
cohorts. When the two cohorts were combined, at a 382.68
(pg/ml)2 cut-off value, the products of Aβ42 and tau achieved
92% accuracy with 96% sensitivity and 90% specificity.
Our results strongly support plasma Aβ42 and tau levels
as having a significant role in AD biomarker development.
Previously, there have been few studies of plasma levels of tau
in AD (Sparks et al., 2012; Zetterberg et al., 2013; Krishnan and
Rani, 2014). The results from these studies showed technical
limitations in measurements of tau levels in plasma. At present,
only the new technologies of SIMOA and IMR have been able
to produce reliable plasma tau measurements (Zetterberg et al.,
2013; Mattsson et al., 2016). In the recent study by Mattsson et al.
using SIMOA to measure tau, the results showed mean values
at 2.58 pg/ml in NCs and 3.12 pg/ml in ADs in the Alzheimer’s
Disease Neuroimaging Initiative (ADNI) cohort, and 5.58 pg/ml
in NCs and 5.37 pg/ml in ADs in the Swedish Biomarkers
for Identifying Neurodegenerative Disorders Early and Reliably
(BioFINDER) study cohort. These values were all much lower
than the values obtained with the IMR-based tau assay in this and
previous studies (Chiu et al., 2013, 2014; Zetterberg et al., 2013).
There were significant increases in plasma tau levels in clinical
ADs compared with NCs and MCI in the ADNI cohort, but
this result was not detected in the BioFINDER cohort (Mattsson
et al., 2016). The distribution of plasma tau levels very much
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FIGURE 2 | Scatter plots of Aβ42 (A) and tau (B) levels in the Banner Sun
Health Research Institute (BSHRI) and National Taiwan University Hospital
(NTUH) cohorts by disease groups.
overlapped between the diagnostic groups. By contrast, the IMR
assayed tau values overlapped less between diagnostic groups;
AD tau levels in the BSHRI cohort were significant with 1.7-fold
increased from NCs and 4-fold in the NTUH cohort; in both
IMR studied cohorts, the IMR tau data was less compressed. The
tau levels in ADs in the combined cohort had median values of
45.12 pg/ml in a range of 21.16–105.03 pg/ml.
This study established that in a group of patients with clinically
diagnosed moderate AD, plasma samples contained elevated tau
compared to NCs, whereas the levels of Aβ42 in the AD groups
had either a small increase (in NTUH cohort) or an increasing
trend (BSHRI cohort). However, the prediction accuracy for ADs
was enhanced by the ratio or product of plasma levels of Aβ42
and tau. The improvement was more pronounced in the United
States (BSHRI) cohort, increasing from 75 to 81% when using
Aβ42 or tau levels alone to 88% when using Aβ42× tau. A smaller
improvement was shown in the NTUH cohorts as its single
analyte measures already had high prediction accuracy (95–97%).
When a logistic regression model was tested in the pooled data,
which spanned a broader age range and disease severity, the
prediction accuracy for clinically diagnosed AD were 93% for
Aβ42× tau.
As the NTUH cohort was not age-matched between the
disease groups, age was included as a covariate for analysis of
disease-group differences using ANCOVA. While significantly
higher plasma Aβ42 was detected in probable ADs than in NCs
in the NTUH cohort, there was only a non-significant trend in
the BSHRI cohort. The lack of significance could be contributed
by greater variability of Aβ42 values in NCs, smaller number of
participants, and data overlap between NC and AD groups.
The most common issues for measurement of small amount of
molecules in the protein-rich media such as plasma and serum are
interference and matrix effects that might result in false high or
low detection of analyte concentrations (Blennow and Zetterberg,
2015a). It is possible that the interactions of antibody-conjugated
magnetic nanobeads and target analyte during the assay are less
prone to be masked by the abundant proteins present in plasma,
as magnetic nanobeads are oscillating rapidly in a magnetic field
under alternate currents. Moreover, the IMR procedure does not
include secondary antibody, which can be potential source of
immunoglobulin cross-reactivity between species.
Plasma or serum Aβ species and tau levels measured
by conventional ELISA assays have been inconsistent in
demonstrating disease-associated differences due to assay
sensitivity and the wide data overlap between groups (Sparks
et al., 2012; Chiu et al., 2013, 2014; Zetterberg et al., 2013;
Krishnan and Rani, 2014; Tzen et al., 2014) The application
of IMR and SQUID technology for AD blood biomarker
development has been a recent invention (Yang et al., 2011; Chiu
et al., 2012, 2013, 2014). The current study is the first side-by-side
comparison of IMR-assayed findings of cohorts from two distinct
ethnic populations.
Plasma Aβ42 levels have been investigated extensively in
autosomal dominant AD and down syndrome, as well as late-
onset AD, using single or multiplex ELISA methods, where
elevated plasma Aβ42 levels and/or Aβ42/40 ratios in patients
with autosomal dominant AD have been reported (Cavani et al.,
2000; Schupf et al., 2001; Coppus et al., 2012; Toledo et al., 2013;
Fleisher et al., 2015; Quiroz et al., 2015). However, studies of
sporadic AD subjects were not consistent, reporting Aβ42 levels
as being unchanged, decreased, or increased (Mehta et al., 2000;
Blennow et al., 2009; Lui et al., 2010; Chiu et al., 2012; Wu
et al., 2012; Toledo et al., 2013; Janelidze et al., 2016; Lovheim
et al., 2016; Poljak et al., 2016). Factors that affect Aβ42 results
include platform-associated limitations such as matrix effect,
interference, and epitope masking (Bibl et al., 2004; Toledo
et al., 2011; Slemmon et al., 2012, 2015; Blennow and Zetterberg,
2015b). Although both ELISA assays and IMR assays are based on
antigen-antibody reactions, IMR assays appears to have unique
capability of detecting modest alterations in plasma Aβ42 levels
possibly due to minimal matrix effect. However, the possibility of
different forms or sub-types of Aβ42 being detected by these assay
platforms cannot be ruled out. It is crucial to confirm plasma
Aβ42 increases in AD in studies with larger subject numbers,
since lower CSF Aβ42 levels have been shown to be very sensitive
marker for pathologically confirmed AD (Shaw et al., 2009).
Disease heterogeneity could be a common problem contributing
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TABLE 3 | Leave-one-out receiver operation characteristics analyses of BSHRI and NTUH data.
BSHRI Sensitivity (95% CI)# Specificity (95% CI)# +LR −LR Accuracy (95% CI)# Age-dependent?
Aβ42 0.56 (0.31, 0.81) 0.81 (0.63, 1.00) 3 0.54 0.69 (0.53, 0.84) Yes
Tau 0.75 (0.56, 0.94) 0.88 (0.69, 1.00) 6.00 0.29 0.81 (0.66, 0.94) No
Aβ42/tau 0.63 (0.38, 0.88) 0.81 (0.63, 1.00) 3.33 0.47 0.72 (0.56, 0.88) No
Aβ42 × tau 0.88 (0.69, 1.00) 0.81 (0.62, 1.00) 4.67 0.15 0.84 (0.72, 0.97) No
NTUH
Aβ42 0.94 (0.84, 1.00) 0.97 (0.92, 1.00) 28.53 0.067 0.96 (0.91, 0.99) Yes
Tau 0.97 (0.90, 1.00) 0.95 (0.89, 1.00) 19.68 0.034 0.96 (0.91, 0.99) No
Aβ42/tau 0.94 (0.84, 1.00) 0.97 (0.92, 1.00) 28.53 0.067 0.96 (0.91, 0.99) No
Aβ42 × tau 1.00 (1.00, 1.00) 0.92 (0.84, 0.98) 12.20 0.00 0.95 (0.89, 0.99) No
#95% CI: Lower, Upper. Abbreviations: CI, confidence interval; +LR, positive likelihood ratio; −LR, negative likelihood ratio.
TABLE 4 | Leave-one-out (LOO) receiver operation characteristics analyses of the pooled data.
Combined cohort Sensitivity (95% CI)# Specificity (95% CI)# AUC (P-value) +LR −LR Accuracy (95% CI)# Age-dependent∗ Cut-off value
Aβ42 0.89 (0.79, 0.98) 0.90 (0.82, 0.96) 0.92 (2.90e-15) 8.60 0.12 0.90 (0.84, 0.94) Yes ∗∗
Tau 0.89 (0.79, 0.98) 0.94 (0.88, 0.99) 0.97 (8.83e-19) 13.76 0.11 0.92 (0.87, 0.96) No >25.41
Aβ42/tau 0.83 (0.72, 0.94) 0.94 (0.88, 0.99) 0.95 (2.11e-17) 12.78 0.18 0.90 (0.84, 0.94) No >0.61
Aβ42 × tau 0.96 (0.89, 1.00) 0.90 (0.83, 0.96) 0.98 (3.07e-19) 9.22 0.047 0.92 (0.87, 0.97) No >382.68
#95% CI: Lower, Upper. Abbreviations: AUC, area under curve; CI, confidence interval; +LR, positive likelihood ratio; −LR, negative likelihood ratio. ∗, The cut-off value
was obtained without the LOO procedure. ∗∗, The cut-off value was a function of age.
to lack of differences between groups in plasma samples (Toledo
et al., 2011). This is inevitable in a complex multi-factorial
disease such as AD, where factors of age, gender, ApoE genotype,
and other pathologies can affect disease progression. The risk
genotype, ApoE e4, has been reported to associate with lower
Aβ42 levels in plasma samples (Sun et al., 2009; Metti et al.,
2013). In this study, we could not establish such relationship
possibly due to too small number of subjects in BSHRI cohort,
as ApoE genotype data were not available from NTUH cohort.
Future study will ensure such data available for assessing the
effects of ApoE genotypes on plasma Aβ and tau levels assayed
by IMR.
The ability for plasma levels of Aβ42 and tau to aid in clinical
diagnosis of AD were evaluated vigorously as performance
metrics in this study, based on areas under the curve (AUC) of
ROC, which were compared using LOO cross-validation to avoid
over-fitting. The use of the logistic model approach with age took
into consideration that the cut-off value of a given plasma analyte
might be age-dependent. The cut-off value will not be a single
value for all ages, but a series of cut-off values corresponding
to different ages, when the age-effect in the logistic model is
significant.
Various combinations of Aβ42, tau, or ptau levels in CSF such
as ratios of tau or ptau to Aβ42 performed better for diagnosis
of AD than single biomarker. This should be expected based
on the known interaction of these molecules in AD. In AD
CSF, Aβ42 levels were decreased and tau or ptau levels were
increased (Hampel et al., 2004; Diniz et al., 2008; Mattsson et al.,
2013; Toledo et al., 2013; Kang et al., 2015). Plasma Aβ42 was
present in a narrow range at low concentrations with small
changes between subjects. Therefore, the product with tau levels
improved the usefulness of plasma Aβ42. This was supported
by AUC analyses of predicting accuracy for clinically diagnosed
ADs. A recent review of CSF biomarker panels indicated that
regression models incorporating various combinations of factors
such as age, gender, baseline MMSE, or ApoE status could
increase similar robustness for the AD diagnosis (Duits et al.,
2014).
There are limitations of this study that should be considered;
the BSHRI cohort was small; both study cohorts were limited
to clinically assessed subjects; and the study was cross-sectional.
Nonetheless, the results are promising due to the high degree
of discrimination between ADs and NCs, supporting that
additional studies are warranted to confirm these findings. Such
discrimination has not been reported for an AD core blood
biomarker previously. Further work is needed (1) to clarify and
confirm the assay ability to identify subjects at preclinical stages
of AD, e.g., MCI; (2) to confirm discrimination AD from other
types of dementia; (3) to track AD in longitudinal studies; (4) to
determine correlation with other biomarkers (e.g., imaging and
CSF markers); and (5) to assess the benefits of disease-modifying
treatments.
CONCLUSION
The results from this side-by-side study supported recent findings
using the IMR platform, and extend the findings to a Caucasian
population. Using ultra-sensitive IMR-based assays, patients
with the clinical diagnosis of late-onset AD dementia could
be identified with a high accuracy rate by combining use of
Aβ42 and tau levels. Further studies are needed in larger study
cohorts for differential diagnosis, early detection, and tracking
of AD.
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